Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Gynecologic Oncology

• Publication date

  1996-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1006/GYNO.1996.0134PMID 8626142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Phase II Trial of 5‐Fluorouracil and High‐Dose Leucovorin in Recurrent Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study

  1995cited by this paper
• Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.

  1995cited by this paper
• Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.

  1994cited by this paper
• Bi-weekly 2-day schedule of high-dose folinic acid, 5-fluorouracil bolus and infusion in pretreated advanced epithelial ovarian cancer: a phase II study.

  1992cited by this paper
• 5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma. A phase II trial of the Gynecologic Oncology Group.

  1992cited by this paper
• 5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma.

  1992cited by this paper
• Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

  1990cited by this paper
• A phase III trial of 5‐fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A mayo clinic/north central cancer treatment group study

  1989cited by this paper

• Exploring the anticancer potential of pyrimidine derivatives via molecular docking and dynamics

  2025cites this paper
• 5-fluorouracil and curcuminoids extract from Curcuma longa L. loaded into nanohydroxyapatite as a drug delivery carrier for SKOV-3 and HepG2 cancer cells treatment

  2023cites this paper
• An in-Depth Analysis of Ovarian Cancer: Pathogenesis and Clinical Manifestation.

  2022cites this paper
• Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives—An In Vitro Study

  2020cites this paper
• RETRACTED ARTICLE: Nanoscale drug delivery strategies for therapy of ovarian cancer: conventional vs targeted

  2019cites this paper
• Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

  2018cites this paper
• Electroanalytical method for the determination of 5-fluorouracil using a reduced graphene oxide/chitosan modified sensor

  2015cites this paper
• Estudo de alterações em células Treg e TH17 no linfonodo drenante de animais com tumores

  2014cites this paper
• Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer

  2013cites this paper
• Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C

  2012cites this paper
• Targeted treatment of recurrent platinum-resistant ovarian cancer : current and emerging therapies

  2010cites this paper
• A Feasibility Study of Weekly Docetaxel with Capecitabine in Ovarian Cancer: A Promising Combination of Two Active Drugs with a Potential for Synergism

  2009cites this paper
• A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.

  2006cites this paper
• Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.

  2004cites this paper
• A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer.

  2004cites this paper
• Liposomal anthracycline treatment for ovarian cancer.

  2004cites this paper
• Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.

  2003cites this paper
• An in vitro examination of a 5-fluorouracil regimen involving continuous venous infusion using cultured cell lines derived from ovarian cancers.

  2000cites this paper
• A phase I/II study of hypofractionated whole abdominal radiation therapy in patients with chemoresistant ovarian carcinoma: Karnofsky score determines treatment outcome.

  2000cites this paper
• 2nd-line-Chemotherapie nach Platin- oder Platin-Paclitaxel-haltiger Primärtherapie beim Ovarialkarzinom: eine systematische Übersicht der publizierten Daten bis 1998

  2000cites this paper
• Cancer Management and Research Dovepress Targeted Treatment of Recurrent Platinum-resistant Ovarian Cancer: Current and Emerging Therapies

  year unknowncites this paper